Background: In 2008, a dedicated American Thoracic Society/European Respiratory Society
task force published a paper on the possible use and limitations of clinical outcomes and …

The American Thoracic Society/European Respiratory Society jointly created a Task Force
on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform …

Clinical phenotyping is currently used to guide pharmacological treatment decisions in
chronic obstructive pulmonary disease (COPD), a personalized approach to care. Precision …

Chronic obstructive pulmonary disease (COPD) remains a leading cause of death
worldwide, yet only one new drug class has been approved in the last decade. However …

Background: This document provides clinical recommendations for the pharmacologic
treatment of chronic obstructive pulmonary disease (COPD). It represents a collaborative …

COPD imposes considerable worldwide burden in terms of morbidity and mortality. In
recognition of this, there is now extensive focus on early diagnosis, secondary prevention …

With the 60th anniversary of the CIBA symposium, it is worth evaluating research questions
that should be prioritized in the future. Coming research initiatives can be summarized in 10 …

PREVIEW Patients with chronic obstructive pulmonary disease (COPD) have more reasons
to be optimistic these days. New drug therapy options in combination with some older …

Introduction. The current pharmacological treatments for the management of stable COPD
permit the reduction of symptoms and frequency and severity of exacerbations, and the …

National guidelines for the pharmacologic treatment of chronic obstructive pulmonary
disease (COPD) can be clarified for busy primary care practitioners who must deal with …